Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced on November 12, 2026, that new two-year findings from the OASISplus clinical programme showed sustained reductions in hereditary angioedema attacks among patients receiving DAWNZERA (donidalorsen). The company reported a 95% overall reduction from baseline in attack rates across its open-label extension cohort and a 71% reduction among patients who switched from other long-term preventive medicines, providing additional evidence about treatment durability following the drug’s regulatory approval.
The findings are being presented at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting in Phoenix, Arizona. They extend the evidence generated by the Phase 3 OASIS-HAE trial, which established the efficacy of donidalorsen against placebo and supported its approval for prevention of hereditary angioedema attacks in adults and adolescents aged 12 years and older. Unlike the original randomised comparison, the latest analyses are based on open-label follow-up and therefore require a different level of evidentiary interpretation.
The commercial significance is also increasing. Ionis reported $37 million in United States DAWNZERA net product sales during the third quarter of 2026 and reaffirmed its full-year sales outlook of $110 million to $120 million. The new data provide clinical context for that launch, particularly as the hereditary angioedema market becomes increasingly competitive around treatment convenience, dosing intervals and sustained disease control.
What do the two-year OASISplus results reveal about sustained hereditary angioedema prevention?
The OASISplus open-label extension enrolled patients continuing from the pivotal OASIS-HAE study. Participants received donidalorsen every four or eight weeks, allowing researchers to examine treatment experience beyond the controlled 24-week period used in the original Phase 3 investigation. The extension provides information about longer-term exposure, attack frequency, treatment persistence and tolerability.
Ionis reported that 84% of participants remained in the open-label extension after two years. Among the 83 patients included in the disclosed analysis, the company observed an overall 95% reduction in hereditary angioedema attack rates compared with baseline across both dosing groups. This represents a substantial reduction within the observed population, although it is not a two-year comparison against an untreated placebo group.
The distinction matters because hereditary angioedema attack frequency can vary between individuals and over time. Patients entering an extension study may also differ from those who discontinue treatment or do not proceed beyond the original trial. Consequently, sustained within-person improvements provide useful evidence of durability but cannot independently establish the magnitude of treatment benefit that would be observed against a concurrent control group after two years.
The high proportion of participants remaining in the programme is an encouraging indicator of treatment continuation within the study. However, retention should not be interpreted as proof that every continuing participant experienced complete disease control or remained free from adverse effects. The reasons for discontinuation, patterns of missing information and characteristics of patients completing follow-up remain relevant to the interpretation.
The results nevertheless add meaningful information beyond the original regulatory trials. Hereditary angioedema is a lifelong condition, and preventive treatment may continue for extended periods. Evidence that favourable attack-rate patterns persist during longer exposure is therefore relevant to clinicians evaluating ongoing treatment strategies.
The latest findings suggest that donidalorsen can maintain substantial reductions in attack frequency among patients who continue treatment. The strength of that conclusion is supported by the longitudinal observations, while its limitations arise from the absence of a concurrent untreated comparison and the possibility of selection effects.
Why is the 71% reduction in the OASISplus switch cohort commercially important?
The OASISplus switch cohort examined patients who transitioned to DAWNZERA from other established long-term hereditary angioedema prophylactic medicines. The previous therapies included lanadelumab, C1-esterase inhibitor treatment and berotralstat. The study used a predefined transition protocol intended to evaluate treatment experience following the switch.
After two years, 80% of patients remained in the switch cohort. Across the 64 participants included in the reported analysis, Ionis observed a 71% overall reduction in hereditary angioedema attack rates compared with baseline while patients were receiving their prior prophylactic therapy. The result suggests that favourable disease control was maintained or improved after treatment transition in the observed population.
However, this is not a randomised head-to-head comparison between donidalorsen and the previous medicines. Patients were selected for switching, and the study did not randomly assign otherwise comparable groups to continue existing treatment or receive DAWNZERA. Differences in baseline disease activity, treatment history and patient selection could therefore influence the observed reduction.
The 71% figure should not be presented as evidence that donidalorsen is 71% more effective than lanadelumab, C1-esterase inhibitor therapy or berotralstat. It reflects a comparison with the switch cohort’s prior-treatment baseline under the study conditions. Establishing comparative superiority would require a different trial design and appropriate statistical controls.
The result is commercially relevant because many patients eligible for new hereditary angioedema treatments are already receiving effective prophylaxis. A newly approved medicine must therefore compete not only against untreated disease but also against established treatment regimens. Evidence from patients with previous preventive treatment experience can help clinicians understand whether switching is feasible and how outcomes may evolve.
Treatment choice may also involve practical considerations. Differences in administration route, injection frequency, previous adverse effects and individual disease control can influence patient preferences. The latest findings may support discussions about available options, but they do not establish which preventive medicine is preferable for every patient.
For Ionis, the switch cohort provides a more clinically relevant commercial narrative than an analysis limited entirely to patients previously receiving no long-term prophylaxis. Its value remains supportive rather than comparative, particularly because the underlying study was open-label.
How does eight-week DAWNZERA dosing influence its clinical differentiation?
DAWNZERA is an antisense oligonucleotide designed to reduce the production of plasma prekallikrein, a protein involved in the pathway responsible for hereditary angioedema attacks. By targeting the messenger RNA associated with prekallikrein production, donidalorsen reduces the availability of a protein contributing to bradykinin generation and swelling episodes. This mechanism differentiates it from therapies acting through other components of the same biological pathway.
The United States prescribing information recommends 80 mg administered by subcutaneous injection every four weeks. It also permits consideration of an 80 mg dose every eight weeks, creating an approved dosing option that may reduce injection frequency for appropriate patients. The practical importance of that flexibility depends on maintaining adequate disease control.
Ionis reported a post hoc analysis involving patients eligible for eight-week dosing during the OASISplus extension and switch studies. Among participants who began the extension receiving donidalorsen every eight weeks, the company observed a 95% overall reduction in attack rates over two years. Ionis described the pattern as consistent with findings in patients receiving treatment every four weeks.
The observations support the durability of the eight-week regimen within the selected study population. Nevertheless, the analysis does not establish statistical equivalence or non-inferiority between the two dosing schedules unless those conclusions were demonstrated through an appropriately designed comparison. Patients eligible for less frequent dosing may also differ from those requiring more frequent treatment.
This qualification is important because dosing frequency is becoming a competitive factor in hereditary angioedema prophylaxis. Patients and clinicians may value fewer injections, but the appropriate interval must be considered alongside disease severity, treatment response and the consequences of breakthrough attacks. Convenience cannot compensate for inadequate disease control.
The approved dosing flexibility could support DAWNZERA’s differentiation, especially for patients seeking to reduce treatment administration burden. However, the long-term commercial advantage will depend on how frequently clinicians select the eight-week schedule and whether patients maintain suitable control under routine clinical conditions.
The OASISplus findings strengthen the available evidence for extended dosing intervals without eliminating the need for individual clinical assessment. They also provide a basis for further research into which patient characteristics may be associated with successful treatment at different frequencies.
How do the new data compare with the original Phase 3 OASIS-HAE efficacy results?
The original OASIS-HAE study was a randomised, double-blind, placebo-controlled Phase 3 investigation evaluating donidalorsen in patients with hereditary angioedema. Participants received 80 mg every four weeks, 80 mg every eight weeks or placebo during the controlled treatment period. The study was designed to establish whether donidalorsen reduced attack rates compared with placebo.
Ionis reported that every-four-week administration reduced the mean monthly hereditary angioedema attack rate by 81% compared with placebo over the primary evaluation period. The every-eight-week regimen produced a 55% reduction relative to placebo, with both comparisons achieving statistical significance. These findings supported the clinical efficacy evidence underlying regulatory approval.
The controlled trial also examined attack severity and the need for acute treatment. In the every-four-week group, Ionis reported an 89% reduction in moderate-to-severe attacks and a 92% reduction in attacks requiring acute treatment during the relevant assessment period. These outcomes are clinically relevant because the burden of hereditary angioedema extends beyond the total number of swelling episodes.
The original trial findings provide the strongest controlled evidence for the treatment’s efficacy. The OASISplus extension adds information about how attack patterns evolve during continued treatment, but the two sets of percentages measure different comparisons. The Phase 3 figures describe treatment effects relative to placebo, while the extension percentages describe changes from baseline in patients receiving active therapy.
Consequently, the 95% two-year reduction should not be interpreted as evidence that donidalorsen became more effective than it was during the randomised Phase 3 study. The longer-term result may reflect sustained disease control within the observed population, but its magnitude cannot be directly compared with the placebo-adjusted primary endpoint without accounting for the differences in design and analysis.
This distinction is particularly important when evaluating highly favourable long-term percentages. Open-label extension studies can produce useful evidence about durability and exposure, but they do not reproduce the statistical protections provided by the original randomised comparator.
Does the two-year safety evidence resolve long-term treatment concerns?
Ionis reported no new safety signals across the disclosed OASISplus analyses. Most treatment-emergent adverse events were described as mild or moderate, and the company reported no serious treatment-emergent adverse events considered related to donidalorsen. These observations provide additional information about longer-term tolerability among patients remaining in the programme.
However, the absence of newly identified safety signals does not mean the approved treatment is free from important risks. DAWNZERA’s United States prescribing information includes warnings concerning hypersensitivity reactions, including anaphylaxis. The medicine is contraindicated in patients with a history of serious hypersensitivity reactions to donidalorsen or its excipients.
The most commonly reported adverse reactions include injection-site reactions, upper respiratory tract infections, urinary tract infections and abdominal discomfort. Their relevance to clinical decision-making depends on frequency, severity and individual patient circumstances. Extended follow-up can help characterise tolerability, but uncommon events may remain difficult to assess in relatively small study populations.
The OASISplus extension included 83 patients in the reported long-term efficacy analysis, while the switch cohort included 64. These numbers provide additional exposure information but are not sufficient to rule out rare adverse reactions across a much larger treated population. Post-marketing safety surveillance therefore remains relevant as commercial use expands.
Patient retention can also influence the apparent tolerability profile of extension studies. Individuals experiencing substantial difficulties with treatment may be less likely to remain enrolled for two years, potentially affecting the characteristics of the population available for long-term analysis. Understanding discontinuation reasons is therefore important when interpreting favourable findings.
The latest evidence supports continued confidence in the observed safety profile under the study conditions. It does not remove the warnings already established in the product label or establish that long-term risk is identical across every patient population.
Why is DAWNZERA’s commercial growth important to Ionis Pharmaceuticals?
Ionis has moved beyond a business model focused principally on licensing RNA-targeted medicines to pharmaceutical partners. It now operates a growing portfolio of independently commercialised medicines, making product sales and launch execution increasingly important to its financial performance. DAWNZERA is a significant part of that transition.
The company reported $37 million in United States DAWNZERA net product sales during the third quarter of 2026. Sales for the first nine months reached $79 million, and Ionis reaffirmed full-year guidance of $110 million to $120 million. The figures indicate that the hereditary angioedema launch is making a measurable contribution to the company’s commercial revenue.
Ionis also reported approximately $1.9 billion in cash, cash equivalents and short-term investments at September 30, 2026. This provides resources for continued commercial expansion and development activities, although the company remains exposed to operating expenditure across its wider portfolio. The scale of available liquidity reduces immediate financing pressure but does not eliminate the need to generate sustainable commercial returns.
The hereditary angioedema market contains several established preventive treatment options, including injectable and oral medicines with different mechanisms and dosing schedules. Clinical differentiation therefore depends on a combination of attack control, tolerability, administration burden and patient preference. Payer coverage and access requirements can also influence which treatments are available in routine practice.
The OASISplus results may support medical education and clinician confidence in long-term donidalorsen use. However, the company will still need to demonstrate that clinical interest translates into continued prescribing and patient retention. Strong efficacy data do not automatically establish that a medicine will achieve the commercial uptake anticipated by management.
International expansion provides another opportunity. Ionis has reported approvals in additional markets, including Europe and Canada, alongside its United States commercial activities. Each jurisdiction presents its own pricing, reimbursement and launch requirements, meaning regulatory approval does not necessarily translate into immediate patient access.
The latest financial guidance suggests that management expects DAWNZERA to remain an important near-term revenue contributor. The next commercial evidence will come from continued quarterly sales, broader reimbursement access and the extent to which patients remain on treatment after initiation.
What will determine DAWNZERA’s long-term position in hereditary angioedema care?
The two-year OASISplus findings provide supportive evidence that substantial reductions in hereditary angioedema attack rates can persist during continued donidalorsen treatment. The switch cohort adds information about patients transitioning from other prophylactic therapies, while the eight-week dosing analysis contributes to understanding an approved option for less frequent administration. Together, these findings broaden the evidence base beyond the original controlled trials.
The limitations remain important. Open-label observations cannot establish comparative superiority, and post hoc dosing analyses do not independently prove equivalence between treatment intervals. Additional real-world evidence may help clarify how patients respond across different clinical settings and treatment histories.
For clinicians, the relevant questions include whether patients maintain adequate disease control, how breakthrough attacks are managed and whether the dosing schedule remains suitable over time. For Ionis, those clinical factors connect directly with treatment persistence and commercial adoption. The company’s revenue growth will depend on translating its approved therapeutic profile into durable patient and prescriber confidence.
DAWNZERA’s pivotal efficacy has already been established through controlled clinical research, while its longer-term evidence continues to develop. The new OASISplus analyses strengthen the case for sustained disease control among observed patients, but the next measure of its value will be how consistently that performance translates into routine clinical practice alongside established hereditary angioedema therapies.
